文献速递特殊人群用药

开发通用胎儿生理药代动力学模型并预测头孢呋辛在母体与胎儿器官的浓度

Development of a Generic Fetal Physiologically Based Pharmacokinetic Model and Prediction of Human Maternal and Fetal Organ Concentrations of Cefuroxime.
PubMed 文献 · Clin Pharmacokinet · 2023-11-14

本研究在开源软件PK-Sim/MoBi中扩展妊娠PBPK模型,新增胎儿脑、心、肝、肺、肾、胃肠道、肌肉和脂肪等隔室,用于预测头孢呋辛在母体血浆、胎儿血浆、羊水及多个胎儿器官中的浓度;模型成功预测了母血、脐带、羊水及胎儿心、肝、肺中的头孢呋辛浓度,但需更多临床PK数据验证。

要点

  • 该通用胎儿PBPK模型基于开源软件构建,可免费重用并按需调整。
  • 模型成功预测头孢呋辛在母血、脐带、羊水及胎儿心、肝、肺的浓度。
  • 模型尚需额外临床PK数据验证以增强可信度。

核心结论

  • 新型妊娠PBPK模型成功预测头孢呋辛在母血、脐带、羊水及胎儿心、肝、肺中的浓度。
  • 该开源通用模型可自由重用和调整,用于辅助临床研究设计或胎儿健康风险评估。

研究设计与样本

  • 在开源软件Open Systems Pharmacology(PK-Sim®/MoBi®)中更新既往妊娠PBPK模型,增加代表胎儿脑、心、肝、肺、肾、胃肠道、肌肉、脂肪及汇总隔室的多重隔室。

主要发现

  • 模型成功预测头孢呋辛在母体血液、脐带、羊水及胎儿心、肝、肺等器官中的浓度。

临床怎么用

  • 该模型可用于辅助设计药物研究相关的临床研究,或预测化学物质在胎儿器官的浓度以支持胎儿健康风险评估。

局限性

  • 需用额外临床PK数据进一步验证模型以建立可信度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Physiologically based pharmacokinetic (PBPK) models for pregnant women have recently been successfully used to predict maternal and umbilical cord pharmacokinetics (PK). Because there is very limited opportunity for conducting clinical and PK investigations for fetal drug exposure, PBPK models may provide further insights. The objectives of this study were to extend a whole-body pregnancy PBPK model by multiple compartments representing fetal organs, and to predict the PK of cefuroxime in the maternal and fetal plasma, the amniotic fluid, and several fetal organs. METHODS: To this end, a previously developed pregnancy PBPK model for cefuroxime was updated using the open-source software Open Systems Pharmacology (PK-Sim®/MoBi®). Multiple compartments were implemented to represent fetal organs including brain, heart, liver, lungs, kidneys, the gastrointestinal tract (GI), muscles, and fat tissue, as well as another compartment lumping organs and tissues not explicitly represented. RESULTS: This novel PBPK model successfully predicted cefuroxime concentrations in maternal blood, umbilical cord, amniotic fluid, and several fetal organs including heart, liver, and lungs. Further model validation with additional clinical PK data is needed to build confidence in the model. CONCLUSIONS: Being developed with an open-source software, the presented generic model can be freely re-used and tailored to address specific questions at hand, e.g., to assist the design of clinical studies in the context of drug research or to predict fetal organ concentrations of chemicals in the context of fetal health risk assessment.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Liu XI, Green DJ, van den Anker J, et al. Development of a Generic Fetal Physiologically Based Pharmacokinetic Model and Prediction of Human Maternal and Fetal Organ Concentrations of Cefuroxime. Clin Pharmacokinet. 2023. PMID: 37962827. doi:10.1007/s40262-023-01323-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。